Rigel Pharmaceuticals Culture Company

Mr. Eldon C. Mayer, III, has been the Chief Commercial Officer and Executive Vice President of Rigel Pharmaceuticals, Inc., since October 2016. Mr. Mayer served as Senior Vice President of Commercial Operations at Questcor Pharmaceuticals, Inc. and served as its Vice President of Commercial Operations since September 2008. Most recently, Mr. Mayer successfully led Questcor Pharmaceuticals' commercial strategy and functions, which included a product launch into multiple indications and physician audiences that resulted in considerable increases in its sales revenue during his tenure. Prior to this, Mr. Mayer held a variety of senior marketing positions with Genentech, Connectics Corporation, Chiron Corporation, ALZA Corporation and Schering Plough. Mr. Mayer was a Management Consultant providing marketing, business and strategy expertise, as well as guidance on operational and launch plans for a variety of biotech and pharmaceutical clients. Mr. Mayer holds an MBA from Syracuse University and a BS from Fairleigh Dickinson University.

Ms. Dolly A. Vance has been General Counsel of Rigel Pharmaceuticals Inc. since January 2003 and as its Executive vice president of Corporate Affairs since May 2010. Ms. Vance has been Corporate Secretary of Rigel Pharmaceuticals, Inc., since January 2007 and served as its compliance officer. She served as Senior Vice President for Rigel Pharmaceuticals, Inc. since January 2007 and served as its Vice President - Intellectual Property from January 2003 to January 2007. Ms. Vance joined Rigel Pharmaceuticals Inc., as Senior Patent Attorney in September 2000 and from January 2002 to December 2002 She served as Associate General Counsel and Director of Intellectual Property. From 1997 to 2000, she was an attorney with the law firm of Flehr Hohbach Test Albritton & Herbert, where she last held the position of partner. From 1995 to 1997, Ms. Vance served as an Associate at the law of firm of Arnall Golden & Gregory and from 1993 to 1995 she was an associate with the law firm of Harness Dickey & Pierce. She worked in various research laboratories, including the laboratory of Norman Davidson at California Institute of Technology. Ms. Vance holds a BA from the University of California, San Diego and a JD from Boston University School of Law.

Ms. Dana Pizzuti has been Senior Vice President of Regulatory Affairs and Clinical Quality Assurance at Rigel Pharmaceuticals, Inc. since August 2017. Ms. Pizzuti has tremendous experience across the broad range of regulatory, clinical, NDA and commercial-stage functions. At Gilead, she managed an organization of 500 worldwide and was responsible for regulatory strategies for all of Gilead's approved and investigational new drugs.

Mr. Nelson Cabatuan is Interim Chief Accounting Officer of Rigel Pharmaceuticals, Inc. since December 31, 2017 and its Vice President of Finance.

Dr. Esteban S. Masuda, Ph.D. has been Senior Vice President of Research at Rigel Pharmaceuticals, Inc. since September 2016. Dr. Masuda held the title of Senior Vice President, Immunology at Rigel. Dr. Masuda spent seven years at DNAX Research Institute of Molecular and Cellular Biology in cytokine biology. He has worked on and led numerous drug discovery projects in inflammatory and allergic diseases and served as the first project leader for fostamatinib, which led to the discovery of that compound. His work has resulted in moving several product candidates into clinical development; various corporate partnerships; 57 publications; and 49 U.S. issued patents. He received a B.S. in biochemistry from University of California, Riverside and a Ph.D. in molecular genetics from Hiroshima University, Japan.

Dr. Thomas A. Raffin, also known as Tom, MD is a Co-Founder at Rigel Pharmaceuticals, Inc. He co-founded Rigel Pharmaceuticals, Inc. in 1996. Dr. Raffin is also a Senior Partner at Telegraph Hill Partners. He joined Telegraph Hill Partners as a Partner in 2001. Dr. Raffin is an Advisor to numerous other companies. He founded the firm. He has spent 28 years as the faculty at Stanford University School of Medicine, where Dr. Raffin is the Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics, served as the Chief of Pulmonary and Critical Care Medicine and a Co-Founder and Director Emeritus of the Stanford University Center for Biomedical Ethics. Dr. Raffin was an Advisor to Cell Therapeutics Inc. from 1993 to 1997, Broncus Technologies from 1997 to 2004, Medica from 1998 to 2002 and Inhale Technologies from 1998 to 2001. He has been a Director of Confirma, Inc. since January 08, 2008, NewLink Genetics Corporation since 1999 and AngioScore, Inc. since April 11, 2006. He serves as Lead Independent Director of NewLink Genetics Corporation. He is a Director of Aquaro Histology, Inc. Dr. Raffin serves as a Director at PneumRx, Inc., Allergene, Apollo Biotechnology and Interface. He has represented THP as a Director at Magstim. He was an Observer on the boards of Estech and Vidacare. Dr. Raffin serves as a Director of TrakCel Ltd. Dr. Raffin was a Director at Merge CAD Inc. since January 2008 and Freedom Innovations, LLC. He served as a Director of LDR Holding Corporation from September 2007 to October 2013. He did his medical residency at the Brigham and Women's Hospital (formerly Peter Bent Brigham Hospital). Dr. Raffin has been an active investigator and researcher in the health care field and has written over 200 articles, numerous chapters and co-authored the book, Intensive Care: Facing the Critical Choices. Over the past two decades he has worked extensively in the healthcare and medical device sectors. He returned to Stanford for Fellowship training in Pulmonary and Critical Care Medicine ('PCCM'). Dr. Raffin holds an M.D. from Stanford University School of Medicine and a B.A. degree from the Stanford University.

Dean Schorno serves as the CFO of Rigel Pharmaceuticals Inc.. Dean started at Rigel Pharmaceuticals Inc. in May of 2018. Dean currently resides in the San Francisco Bay Area.